Clovis Oncology Long Term Debt 2010-2022 | CLVSQ

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Clovis Oncology long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Clovis Oncology long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$213.3B
Amgen (AMGN)	$158.5B
Gilead Sciences (GILD)	$134.6B
Vertex Pharmaceuticals (VRTX)	$118.1B
Bristol Myers Squibb (BMY)	$96.4B
CSL (CSLLY)	$81.2B
GSK (GSK)	$74.3B
Regeneron Pharmaceuticals (REGN)	$58.6B
Alnylam Pharmaceuticals (ALNY)	$41.8B
Argenex SE (ARGX)	$34.6B
BioNTech SE (BNTX)	$26.4B
Royalty Pharma (RPRX)	$20B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.3B
Illumina (ILMN)	$15.2B
Genmab (GNMSF)	$14.3B
Genmab (GMAB)	$14B
Incyte (INCY)	$13.1B
Exelixis (EXEL)	$12.1B
Moderna (MRNA)	$12.1B
BioMarin Pharmaceutical (BMRN)	$11B
QIAGEN (QGEN)	$10.7B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.4B
Exact Sciences (EXAS)	$9.5B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.2B
Roivant Sciences (ROIV)	$7.8B
Legend Biotech (LEGN)	$7.6B